ADMA
ADMA BIOLOGICS, INC.Company Information
- Company Name
- ADMA BIOLOGICS, INC.
- CIK
- CIK0001368514
- Category
- Large accelerated filer
- Ticker: Exchange
- ADMA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ADMA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-27
- Last sale
- 2026-03-16
- Shares purchased (TTM)
- 38,400
- Shares sold (TTM)
- 423,845
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 203,553,999
- Shares outstanding
- 236,072,751
- Ownership
- 86.23%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 0.86%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 136 | 138 | 88 | 61 | 90 | 72 | 103 | 87 | 88 | 45 | 51 | 74 | ||||||
| Accounts Receivable Net Current | 138 | 136 | 158 | 138 | 110 | 99 | 50 | 50 | 30 | 50 | 27 | 31 | ||||||
| Inventory Net | 239 | 222 | 206 | 197 | 191 | 172 | 170 | 172 | 180 | 178 | 173 | 163 | ||||||
| Prepaid Expense And Other Assets Current | 15 | 15 | 7 | 7 | 8 | 9 | 8 | 10 | 6 | 4 | 5 | 5 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | 0 | 0 | 7 | - | - | - | 0 | - | - | - | - | - | ||||||
| Assets Current | 528 | 511 | 467 | 403 | 400 | 352 | 331 | 318 | 304 | 276 | 257 | 274 | ||||||
| Property Plant And Equipment Net | 67 | 65 | 65 | 70 | 58 | 58 | 55 | 54 | 54 | 55 | 54 | 55 | ||||||
| Intangible Assets Net Excluding Goodwill | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Deferred Income Tax Assets Net | 70 | 70 | 73 | 74 | 79 | 81 | 84 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 6 | 6 | 7 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 10 | 10 | ||||||
| Assets | 684 | 665 | 624 | 569 | 558 | 511 | 489 | 391 | 376 | 351 | 329 | 349 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 32 | 21 | 23 | 24 | 30 | 21 | 20 | 16 | 14 | 17 | 16 | 11 | ||||||
| Accrued Liabilities And Other Liabilities | 39 | 49 | 40 | 29 | 44 | 32 | 34 | 28 | 28 | 34 | 33 | 30 | ||||||
| Contract With Customer Liability Current | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | ||||||
| Long Term Debt Current | 4 | 3 | 3 | 2 | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 0 | 0 | 3 | - | - | - | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 76 | 74 | 70 | 56 | 75 | 53 | 56 | 45 | 44 | 53 | 50 | 42 | ||||||
| Senior Long Term Notes | - | - | - | - | 73 | 73 | 72 | 101 | 131 | 131 | 131 | 142 | ||||||
| Long Term Debt Noncurrent | 193 | 194 | 69 | 70 | - | - | 72 | - | - | - | - | - | ||||||
| Deferred Revenue Noncurrent | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | 6 | 6 | 7 | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 10 | 10 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 276 | 275 | 147 | 138 | 160 | 137 | 140 | 159 | 188 | 197 | 194 | 198 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -188 | -143 | -32 | -23 | -15 | - | 0 | - | 0 | - | - | - | ||||||
| Additional Paid In Capital | 675 | 650 | 671 | 665 | 661 | 655 | 658 | 652 | 645 | 642 | 641 | 640 | ||||||
| Retained Earnings Accumulated Deficit | -79 | -116 | -162 | -211 | -247 | -282 | -309 | -420 | -456 | -488 | -506 | -489 | ||||||
| Stockholders Equity | 408 | 390 | 477 | 431 | 398 | 373 | 349 | 232 | 188 | 154 | 135 | 151 | ||||||
| Liabilities And Stockholders Equity | 684 | 665 | 624 | 569 | 558 | 511 | 489 | 391 | 376 | 351 | 329 | 349 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Shares Outstanding | 225 | 232 | 238 | 238 | 239 | 239 | 237 | 236 | 233 | 232 | 226 | 226 | ||||||
| Common Stock Shares Issued | 241 | 241 | 240 | 240 | 239 | 239 | 237 | 236 | 233 | 232 | 226 | 226 | ||||||
| Treasury Stock Common Shares | 16 | 9 | 2 | 1 | 1 | - | 0 | - | 0 | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialADMA BIOLOGICS, INC. (ADMA) — SEC Financial Statements & Analysis
ADMA BIOLOGICS, INC. (ADMA) is a biological products, (no diagnostic substances) company, incorporated in DE. ADMA BIOLOGICS, INC. trades on Nasdaq as: ADMA. ADMA BIOLOGICS, INC. (ADMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, ADMA BIOLOGICS, INC. carries a market cap of $1.91B, a P/E ratio of 11.31x, a P/B ratio of 4.68x, a P/S ratio of 3.73x, an enterprise value of $1.97B, and an EV/EBITDA multiple of 8.49x. On profitability, it posts a gross margin of 64.71%, an operating margin of 43.82%, a net margin of 32.98%, a Return on Equity (ROE) of 41.90%, a Return on Assets (ROA) of 27.19%, and a Return on Invested Capital (ROIC) of 43.99%. Per share, it reports EPS of $0.74, diluted EPS of $0.73, free cash flow per share of $0.51, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 8.04% year-over-year, net income growth of -19.13% year-over-year, and EPS growth of -14.43% year-over-year. On the balance sheet, it maintains a current ratio of 6.97x, a quick ratio of 3.62x, working capital of $452.45M, a debt-to-equity ratio of 0.68x, a debt ratio of 0.4, an interest coverage ratio of 25.44x, free cash flow of $116.47M (TTM), and net debt of $60.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.91B
- P/E TTM
- 11.31x
- EPS TTM
- $0.74
- P/B TTM
- 4.68x
- ROE TTM
- 41.90%
- ROA TTM
- 27.19%
- Debt To Equity
- 0.68x
- Free Cash Flow TTM
- $116.47M
- Net Revenue TTM Growth 1Y
- 8.04%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ADMA BIOLOGICS, INC. in?
ADMA BIOLOGICS, INC. (ADMA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ADMA trade on?
ADMA BIOLOGICS, INC. (ADMA) trades on the Nasdaq.
Where is ADMA BIOLOGICS, INC. incorporated?
ADMA BIOLOGICS, INC. is incorporated in DE.
When was ADMA BIOLOGICS, INC. (ADMA)'s most recent SEC filing?
ADMA BIOLOGICS, INC. (ADMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is ADMA's market cap?
ADMA BIOLOGICS, INC. (ADMA) has a market capitalization of $1.91B as of 2026-06-30.
What is ADMA's P/E ratio?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month P/E ratio is 11.31x as of 2026-06-30.
What is ADMA's EPS (earnings per share)?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month EPS is $0.74 as of 2026-06-30.
What is ADMA's ROE (return on equity)?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month Return on Equity (ROE) is 41.90% as of 2026-06-30.
What is ADMA's ROA (return on assets)?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month Return on Assets (ROA) is 27.19% as of 2026-06-30.
What is ADMA's ROIC (return on invested capital)?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month Return on Invested Capital (ROIC) is 43.99% as of 2026-06-30.
What is ADMA's EV/EBITDA?
ADMA BIOLOGICS, INC. (ADMA)'s trailing twelve month EV/EBITDA is 8.49x as of 2026-06-30.